313 related articles for article (PubMed ID: 15727423)
41. The IL-4 and IL-13 pseudomonas exotoxins: new hope for brain tumor therapy.
Shimamura T; Husain SR; Puri RK
Neurosurg Focus; 2006 Apr; 20(4):E11. PubMed ID: 16709016
[TBL] [Abstract][Full Text] [Related]
42. Convection-enhanced delivery of interleukin-13 receptor-directed cytotoxin for malignant glioma therapy.
Kioi M; Husain SR; Croteau D; Kunwar S; Puri RK
Technol Cancer Res Treat; 2006 Jun; 5(3):239-50. PubMed ID: 16700620
[TBL] [Abstract][Full Text] [Related]
43. Biological intratumoral therapy for the high-grade glioma part I: intratumoral delivery and immunotoxins.
Loya J; Zhang C; Cox E; Achrol AS; Kesari S
CNS Oncol; 2019 Nov; 8(3):CNS38. PubMed ID: 31747788
[TBL] [Abstract][Full Text] [Related]
44. Convection-enhanced delivery for the treatment of glioblastoma.
Vogelbaum MA; Aghi MK
Neuro Oncol; 2015 Mar; 17 Suppl 2(Suppl 2):ii3-ii8. PubMed ID: 25746090
[TBL] [Abstract][Full Text] [Related]
45. Convection-enhanced delivery of polyethylene glycol-coated liposomal doxorubicin: characterization and efficacy in rat intracranial glioma models.
Kikuchi T; Saito R; Sugiyama S; Yamashita Y; Kumabe T; Krauze M; Bankiewicz K; Tominaga T
J Neurosurg; 2008 Nov; 109(5):867-73. PubMed ID: 18976076
[TBL] [Abstract][Full Text] [Related]
46. Convection-enhanced delivery to achieve widespread distribution of viral vectors: Predicting clinical implementation.
Debinski W; Tatter SB
Curr Opin Mol Ther; 2010 Dec; 12(6):647-53. PubMed ID: 21154156
[TBL] [Abstract][Full Text] [Related]
47. Convection-enhanced delivery of free gadolinium with the recombinant immunotoxin MR1-1.
Ding D; Kanaly CW; Bigner DD; Cummings TJ; Herndon JE; Pastan I; Raghavan R; Sampson JH
J Neurooncol; 2010 May; 98(1):1-7. PubMed ID: 19898744
[TBL] [Abstract][Full Text] [Related]
48. Distribution kinetics of targeted cytotoxin in glioma by bolus or convection-enhanced delivery in a murine model.
Kawakami K; Kawakami M; Kioi M; Husain SR; Puri RK
J Neurosurg; 2004 Dec; 101(6):1004-11. PubMed ID: 15597761
[TBL] [Abstract][Full Text] [Related]
49. Current status of local therapy in malignant gliomas--a clinical review of three selected approaches.
Juratli TA; Schackert G; Krex D
Pharmacol Ther; 2013 Sep; 139(3):341-58. PubMed ID: 23694764
[TBL] [Abstract][Full Text] [Related]
50. Local convection-enhanced delivery of an anti-CD40 agonistic monoclonal antibody induces antitumor effects in mouse glioma models.
Shoji T; Saito R; Chonan M; Shibahara I; Sato A; Kanamori M; Sonoda Y; Kondo T; Ishii N; Tominaga T
Neuro Oncol; 2016 Aug; 18(8):1120-8. PubMed ID: 26917236
[TBL] [Abstract][Full Text] [Related]
51. Convection enhanced delivery for the treatment of malignant gliomas: symposium review.
Vogelbaum MA
J Neurooncol; 2005 May; 73(1):57-69. PubMed ID: 15933820
[TBL] [Abstract][Full Text] [Related]
52. A novel bispecific immunotoxin delivered by human bone marrow-derived mesenchymal stem cells to target blood vessels and vasculogenic mimicry of malignant gliomas.
Zhang Y; Sun X; Huang M; Ke Y; Wang J; Liu X
Drug Des Devel Ther; 2015; 9():2947-59. PubMed ID: 26089644
[TBL] [Abstract][Full Text] [Related]
53. Convection-enhanced delivery for treatment of brain tumors.
Ferguson SD; Foster K; Yamini B
Expert Rev Anticancer Ther; 2007 Dec; 7(12 Suppl):S79-85. PubMed ID: 18076322
[TBL] [Abstract][Full Text] [Related]
54. Poor drug distribution as a possible explanation for the results of the PRECISE trial.
Sampson JH; Archer G; Pedain C; Wembacher-Schröder E; Westphal M; Kunwar S; Vogelbaum MA; Coan A; Herndon JE; Raghavan R; Brady ML; Reardon DA; Friedman AH; Friedman HS; Rodríguez-Ponce MI; Chang SM; Mittermeyer S; Croteau D; Puri RK;
J Neurosurg; 2010 Aug; 113(2):301-9. PubMed ID: 20020841
[TBL] [Abstract][Full Text] [Related]
55. Convection-enhanced delivery of Ls-TPT enables an effective, continuous, low-dose chemotherapy against malignant glioma xenograft model.
Saito R; Krauze MT; Noble CO; Drummond DC; Kirpotin DB; Berger MS; Park JW; Bankiewicz KS
Neuro Oncol; 2006 Jul; 8(3):205-14. PubMed ID: 16723630
[TBL] [Abstract][Full Text] [Related]
56. Effects of convection-enhanced delivery of bevacizumab on survival of glioma-bearing animals.
Wang W; Sivakumar W; Torres S; Jhaveri N; Vaikari VP; Gong A; Howard A; Golden EB; Louie SG; Schönthal AH; Hofman FM; Chen TC
Neurosurg Focus; 2015 Mar; 38(3):E8. PubMed ID: 25727230
[TBL] [Abstract][Full Text] [Related]
57. Adjuvant convection-enhanced delivery for the treatment of brain tumors.
Kreatsoulas D; Damante M; Cua S; Lonser RR
J Neurooncol; 2024 Jan; 166(2):243-255. PubMed ID: 38261143
[TBL] [Abstract][Full Text] [Related]
58. A novel implantable catheter system with transcutaneous port for intermittent convection-enhanced delivery of carboplatin for recurrent glioblastoma.
Barua NU; Hopkins K; Woolley M; O'Sullivan S; Harrison R; Edwards RJ; Bienemann AS; Wyatt MJ; Arshad A; Gill SS
Drug Deliv; 2016; 23(1):167-73. PubMed ID: 24786643
[TBL] [Abstract][Full Text] [Related]
59. Safety and efficacy of convection-enhanced delivery of ACNU, a hydrophilic nitrosourea, in intracranial brain tumor models.
Sugiyama S; Yamashita Y; Kikuchi T; Saito R; Kumabe T; Tominaga T
J Neurooncol; 2007 Mar; 82(1):41-7. PubMed ID: 17031554
[TBL] [Abstract][Full Text] [Related]
60. Convection-enhanced and local delivery of targeted cytotoxins in the treatment of malignant gliomas.
Muro K; Das S; Raizer JJ
Technol Cancer Res Treat; 2006 Jun; 5(3):201-13. PubMed ID: 16700617
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
